1. Home
  2. GDRX vs NTLA Comparison

GDRX vs NTLA Comparison

Compare GDRX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GoodRx Holdings Inc.

GDRX

GoodRx Holdings Inc.

HOLD

Current Price

$2.76

Market Cap

913.1M

Sector

Technology

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.07

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDRX
NTLA
Founded
2011
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
913.1M
986.9M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
GDRX
NTLA
Price
$2.76
$9.07
Analyst Decision
Buy
Buy
Analyst Count
11
22
Target Price
$5.25
$19.83
AVG Volume (30 Days)
1.8M
4.5M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
N/A
Revenue
$800,651,000.00
$57,528,000.00
Revenue This Year
$2.30
$1.96
Revenue Next Year
$2.91
N/A
P/E Ratio
$32.60
N/A
Revenue Growth
1.30
33.52
52 Week Low
$2.61
$5.90
52 Week High
$5.81
$28.25

Technical Indicators

Market Signals
Indicator
GDRX
NTLA
Relative Strength Index (RSI) 38.31 40.92
Support Level $2.62 $9.15
Resistance Level $2.97 $9.68
Average True Range (ATR) 0.09 0.53
MACD 0.05 0.40
Stochastic Oscillator 39.44 56.03

Price Performance

Historical Comparison
GDRX
NTLA

About GDRX GoodRx Holdings Inc.

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: